CLINICIANS’ GUIDE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Clinicians’ Guide to Chronic Obstructive Pulmonary Disease

Volumn , Issue , 2005, Pages 1-132

  Howes, Timothy Q ^a   Bellamy, David ^b  

^a O and G   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881267093     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b13274     Document Type: Book

References (174)

1. American Thoracic Society (1995) ATS COPD Guidelines. Am J Respir Crit Care Med 152, S77–120.
2. British Thoracic Society (1997) BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 52(Suppl 5), S1–28.
3. The BTS COPD Consortium (2004) Chronic Obstructive Pulmonary Disease:National clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 59(Suppl 1), 1–232.
4. Fabbri LM, Hurd SS (2003) Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Resp J 22, 1–2.
5. Guite HF, Burney PG (1996) Accuracy of recording of deaths from asthma in the UK: The false negative rate. Thorax 51(9), 924–8.
6. Peleman RA, Rytila PH, Kips JC, Joos GF, Pauwels RA (1999) The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 13, 839–43.
7. Stockley RA (2003) Neutrophils and the pathogenesis of COPD Chest 121, 151S–5S.
8. Keatings VM, Collins PD, Scott DM, Barnes PJ (1996) Differences in interleukin-8 and tumour necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153, 530–4.
9. Mueller R, Chanez P, Campbell AM, Bousquet J, Heusser C, Bullock GR (1996) Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med 90, 79–85.
10. Yamamoto C, Yoneda T, Yoshikawa M et al. (1997) Airway inflammation in COPD assessed by sputum levels of interleukin 8. Chest 112, 505–10.
11. Shapiro SD (1994) Elastolytic metalloproteases produced by human mononuclear phagocytes. Potential role in destructive lung disease. Am J Respir Crit Care Med 150, S160–4.
12. MacNee W (2000) Oxidants/antioxidants and COPD. Chest 117(5 Suppl 1), 303S–17S.
13. Suki B, Lutchen KR, Ingenito EP (2004) On the progressive nature of emphysema; roles of proteases, inflammation and mechanical forces. Am J Respir Crit Care Med 168, 516–21.
14. Hensley MJ, Saunders NA, eds (1989) Clinical Epidemiology of Chronic Obstructive Pulmonary Disease. New York:Marcel Decker.
15. Weitzenblum E (2003) Chronic cor pulmonale. Heart 89, 225–30.
16. Barnes PJ (2004) Corticosteroid resistance in chronic obstructive airways disease: inactivation of histone deacetylase. Lancet 363 (9410), 731–3.
17. Buist AS, Vollmer VM (1994) Smoking and other risk factors. In: Murray JF, Nadel JA, eds. Textbook of Respiratory Medicine. Philadelphia: WB Sanders, 1259–87.
18. Chen JC, Mannino MD (1999) Worldwide epidemiology of chronic obstructive pulmonary disease. Curr Opin Pulmon Med 5, 93–9.
19. General Practice Research Database: http://www.statistics.gov.uk/STATISTICS/.
20. Thom TJ (1989) International comparisons in COPD mortality. Am Rev Respir Dis 140, S27–34.
21. Mannino DM, Ford ES, Redd SC (2003) Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 114 (9), 758–62.
22. Amoli K (1998) Bronchopulmonary disease in Iranian housewives chronically exposed to indoor smoke. Eur Resp J 11, 659–63.
23. Behera D, Jindal SK (1991) Respiratory symptoms in Indian women using domestic cooking fuels. Chest 100, 385–8.
24. Dennis R, Maldonado D, Norman S, Baena E, Martinez G (1996) Woodsmoke exposure and risk for obstructive airways disease among women. Chest 109, 115–19.
25. Pandey MR (1984) Domestic smoke pollution and chronic bronchitis in a rural community of the Hill Region of Nepal. Thorax 39, 337–9.
26. Perez-Padilla R, Regalado U, Vedal S et al. (1996) Exposure to biomass smoke and chronic airways disease in Mexican women. Am J Res Crit Care Med 154, 701–6.
27. Samet JM, Marbury M, Spengier J (1987) Health effects and sources of indoor air pollution. Am Rev Respir Dis 138, 1486–508.
28. Burrows B, Knudson RJ, Cline MG, Lebowitz MD (1977) Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 115, 195–205.
29. Higgins MW, Thom T (1989) Incidence, prevalence and mortality: intra and inter-country differences. In: Hensley M, Saunders N, eds. Clinical Epidemiology of Chronic Obstructive Pulmonary Disease. New York: Marcel Dekker, 23–43.
30. Leuenberger P, Schwartz J, Ackerman-Liebrich U et al. (1994) Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study) Swiss Study on Air Pollution and Lung Diseases in Adults: SAPALDIA team. Am J Respir Crit Care Med 150, 1222–8.
31. US Surgeon General (1984) The Health Consequences of Smoking: Chronic Obstructive Pulmonary Disease. Publication No. 84-50205. Washington, DC: US Department of Health and Human Services.
32. Humerfelt S, Eide GE, Gulsvik A (1998) Association of years of occupational quartz exposure with spirometric airflow limitation in Norwegian men aged 30–46 years. Thorax 53, 649–55.
33. US Centers for Disease Control and Prevention (1995) Criteria for a Recommended Standard: Occupational Exposure to Respirable Coal Mine Dust. Publication No. 95-106.Morgantown: National Institute of Occupational Safety and Health.
34. Calverly PMA (1998) Chronic Obstructive Pulmonary Disease: the Key Facts. London: British Lung Foundation.
35. Murray CJL, Lopez AD, eds (1996) The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press.
36. National Heart, Lung and Blood Institute (1998) Morbidity and Mortality: Chartbook on Cardiovascular, Lung and Blood Diseases. Bethesda: US Department of Health and Human Services, Public Health Service, National Institutes of Health (http://www.nhibi.nih.gov/nhlbi/seiin/other/cht-book/htm).
37. Soriano JR, Maier WC, Egger P et al. (2000) Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 55, 789–94.
38. Murray CJL, Lopez AD (1996) Evidence-based health policy – lessons from the Global Burden of Disease Study. Science 274, 740–3.
39. Badgett RC, Tanaka DV, Hunt DK (1995) et al. Can moderate chronic obstructive pulmonary disease be diagnosed by history and physical findings alone? Am J Med 152, 1107–36.
40. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA (1999) Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54, 581–6.
41. Burrows B, Niden AH, Barclay WR, Kasik JE (1965) Chronic obstructive lung disease II. Relationships of clinical and physiological findings to the severity of airways obstruction. Am Rev Respir Dis 91, 665–78.
42. Elliott MW, Adams L, Cockcroft A, MacRae KD, Murphy K, Guz A (1991) The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. Am Rev Respir Dis 144, 826–32.
43. Georgopoulos D, Anthonisen NR (1991) Symptoms and signs of COPD. In: Cherniack NS, ed. Chronic Obstructive Pulmonary Disease. Toronto: WB Saunders, 357–63.
44. Simon PM, Schwartstein RM, Weiss JW, Fencl V, Teghtsoonian M, Weinberger SE (1990) Distinguishable types of dyspnoea in patients with shortness of breath. Am Rev Respir Dis 142, 1009–14.
45. Anthonisen NR, Wright EC (1986) Bronchodilator response in chronic obstructive pulmonary disease: Am Rev Respir Dis 133, 814–19.
46. Reis AL (1982) Response to bronchodilators. In: Clausen J, ed. Pulmonary Function Testing: Guidelines and Controversies. New York: Academic Press, 215–21.
47. Sourk RL, Nugent KM (1983) Bronchodilator testing: confidence intervals derived from placebo inhalations. Am Rev Respir Dis 128, 153–7.
48. Birring SS, Brightling CE, Bradding P et al. (2002) Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary diseases in non-smokers: a descriptive study. Am J Respir Crit Care Med 166(8), 1078–83.
49. Copley SJ, Wells AU, Muller NL et al. (2002) Thinsection CT in obstructive pulmonary disease: discriminatory value. Radiology 223(3), 812–19.
50. Hansell DM (2001) Small airways diseases: detection and insights with computed tomography. Eur Respir J 17, 1294–313.
51. Kinesella M, Muller NL, Abboud RT et al. (1990) Quantitation of emphysema by computed tomography using a ‘density mask’ program and correlation with pulmonary function tests. Chest 97(2), 315–20.
52. Frazier SC (2005) Implications of the GOLD report for chronic obstructive lung disease for the home care clinician. Home Healthcare Nurse 23(2), 109–14.
53. Crapo RO (1994) Pulmonary function testing. N Eng J Med 331(1), 25–30.
54. National Institute for Clinical Excellence (NICE) (2004) Chronic Obstructive Pulmonary Disease: National clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 59(Suppl 1), 1–232.
55. Quanjer PH, Tammeling GJ, Cotes JE et al. (1993) Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society [see comment]. [Review] [290 refs]. Eur Resp J 16(Suppl1), 5–40.
56. Auerbach O, Hammond EC, Garfinkel L, Benante C (1972) Relation of smoking and age to emphysema.Whole-lung section study. N Engl J Med 286, 853–7.
57. Brydak LB, Tadeusz S, Magdalena M (2004) Antibody response to influenza vaccination in healthy adults. Viral Immunology 17(4), 609–15.
58. Lebowitz MD, Burrows B (1977) Quantitative relationships between cigarette smoking and chronic productive cough. Int J Epidemiol 6, 107–13.
59. Sherill DL, Lebowitz MD, Burrows B (1990) Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med 11, 375–87.
60. Tobacco Advisory Group of The Royal College of Physicians (2002) Report of the Tobacco Advisory Group of The Royal College of Physicians. London: Royal College of Physicians.
61. World Health Organization (1999) Tobacco-free Initiative: Policies for Public Health. Geneva: World Health Organization (available from http://www.who/int/toh/worldnottobacco99).
62. Anthonisen NR, Connett JE, Kiley JP et al. (1994) Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. JAMA 272, 1497–505.
63. Baillie AJ, Mattick RP, Hall W, Webster P (1994) Meta-analytic review of the efficacy of smoking cessation interventions. Drug Alcohol Rev 13, 157–70.
64. Glynn TJ, Manley MW (1990) How to Help Your Patients Stop Smoking. A National Cancer Institute Manual for Physicians. NIH Publication No. 90-3064. Bethesda: US Department of Health and Human Services Public Health Service, National Institutes of Health, National Cancer Institute.
65. Fiore MC, Smith SS, Jorenby DE, Baker TB (1994) The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 271, 1940–7.
66. Tashkin D, Kanner R, Bailey W et al. (2001) Smoking cessation in patients with chronic obstructive pulmonary disease: a double blind, placebo-controlled, randomized trial. Lancet 19, 357 (9268), 1571–5.
67. Chen JC, Mannino MD (1999) Worldwide epidemiology of chronic obstructive pulmonary disease. Curr Opin Pulm Med 5, 93–9.
68. Nathan RA, Geddes D, Woodhead M (2001) Management of influenza in patients with asthma or chronic obstructive pulmonary disease. Ann Allergy Asthma Immunol 87(6), 447–54, 487.
69. Tata LJ, West J, Harrison T, Farrinton P, Smith C, Hubbard R (2003) Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax 58(10), 835–9.
70. Barnes PJ (1995) Bronchodilators; basic pharmacology. In: Calverley PMA, Pride NB, eds: Chronic Obstructive Pulmonary Disease. London: Chapman and Hall, 391–417.
71. Hay JG, Stone P, Carter J et al. (1992) Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 5, 659–64.
72. Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad JH, Tattersfeld AE (1998) High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 138, 850–5.
73. Cazzola M, Matera MG, Santangela G, Vinciguerra A, Rossi F, D’Amato G (1995) Salmeterol and formoterol in partly reversible severe chronic obstructive pulmonary disease: a dose response study. Respir Med 89, 357–62.
74. COMBIVENT Inhalation Aerosol Study Group (1994) In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial: Chest 105, 1411–19.
75. Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R (1999) Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 64, 457–64.
76. McKay SE. Howie CA, Thomson AH, Whiting B, Addis GJ (1993) Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 48, 227–32.
77. Moxham J (1998) Aminophylline and the respiratory muscles: an alternative view. Clin Chest Med 9(2), 325–36.
78. Murciano D, Auclair MH, Pariente R, Aubier M (1998) A randomised controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 320, 1521–5.
79. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320, 1297–303.
80. Jones PW, Willits LR, Burge PS, Calverley PM (2003) Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 21, 68–73.
81. Senderovitz T, Vestbo J, Frandsen J et al. (1999) Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease: The Danish Society of Respiratory Medicine. Respir Med 93, 715–18.
82. Calverley P, Pauwels R, Vestbo J et al. (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361, 449–56.
83. Mahler DA, Wire P, Horstman D et al. (2002) Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166(8), 1084–91.
84. Szafranski W, Cukier A, Ramirez A et al. (2003) Efficacy and safety of budesonide/ formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21, 74–81.
85. Brusacsco V, Hodder R, Miravitalles M, Korducki L, Towse L, Kesten S (2003) Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD Thorax 58, 399–404.
86. Cooper CB, Tashkin DP (2005) Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease BMJ 330, 640–644.
87. Tashkin DP, Cooper CB (2004) The role of long acting bronchodilators in the management of stable COPD Chest 125, 249–59.
88. Barr RG, Bourbeau J, Camargo CA, Ram FSF (2005) The Cochrane Database of Systematic Reviews Issue 2. Art. No 2. Chichester, UK: John Wiley & Sons.
89. Hansen NC, Skriver A, Brorsen-Riis, L. et al. (1994) Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 88, 531–5.
90. Poole PJ, Black PN (2000) Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev (available from URL http://www.updatesoftware. com).
91. Medical Research Council (1981) Long term domiciliary oxygen therapy in chronic hypoxic corpulmonale complicating chronic bronchitis and emphysema. Report of the MRC Working Party. Lancet i, 681–6.
92. Nocturnal Oxygen Therapy Trial Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 93, 391–8.
93. Tarpy SP, Celli BR (1995) Long-term oxygen therapy. N Engl J Med 333, 710–14.
94. Weitzenblum E., Sautegaeu A, Ehrhart M, Mammosser M, Pelletier A (1985) Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 131, 493–8.
95. Zielinski J, Tobiasz M., Hawrylkiewicz I, Sliwinski P, Palasiewicz G (1998) Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 113, 65–70.
96. Consensus Conference Report (1999) Clinical indications for non-invasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation. Chest 116, 521–34.
97. Elliott MW (2002) Non-invasive ventilation in chronic ventilatory failure due to chronic obstructive pulmonary disease. Eur Respir J 20, 511–14.
98. American Thoracic Society (1999) Pulmonary rehabilitation – 1999. Am J Respir Med 159, 1666–82.
99. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA (1999) Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54(7), 581–6.
100. Borg GAV (1982) Psychophysical basis of perceived exertion. Med Sci Sports Exerc 14, 377–81.
101. Celli BR (1995) Pulmonary rehabilitation in patients with COPD. Am Respir Crit Care Med 152, 861–4.
102. Fishman AP (1994) Pulmonary rehabilitation research. Am J Respir Crit Care Med 149, 825–33.
103. Goldstein RS, Gort EH, Stubbing D, Avendano MA, Guyatt GH (1994) Randomised controlled trial of respiratory rehabilitation. Lancet 344, 1394–7.
104. Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS (1996) Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 348, 1115–19.
105. Morgan MDL, Calverley PMA, Clark CJ et al. (2001) Pulmonary rehabilitation: BTS statement. Thorax 56, 827–34.
106. Pulmonary Rehabilitation Guidelines Panel, American College of Chest Physicians/American Association of Cardiovascular and Pulmonary Rehabilitation (1997) Pulmonary rehabilitation: joints ACCP/AACVPR evidence-based guidelines. Chest 112, 1363–96.
107. Brantigan OC, Mueller E, Kress MB (1959) A surgical approach to pulmonary emphysema. Am Rev Resp Dis 80 (1, Part 2), 194–206.
108. Geddes D, Davies M, Koyama H et al. (2000) Effect of lung volume reduction surgery in patients with severe emphysema. N Engl J Med 343, 239–45.
109. Hensley M, Coughlan JL, Davies HR, Gibson P (1999) Lung volume reduction surgery for diffuse emphysema. The Cochrane Database of Systemic Reviews Issue 4, Art. No.: CD001001. DoI: 10. 1002/14651858. CD001001.
110. Little AG, Swain JA, Nino JJ, Prabhu RD, Schlachter MD, Marcia TC (1995) Reduction pneumonoplasty for emphysema. Early results. Ann Surg 222(3), 365–71; discussion 371–4.
111. National Emphysema Treatment Trial Research Group (2001) Patients at high risk of death after lung volume reduction surgery. N Engl J Med 345, 1075–83.
112. Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR (1999) International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 66: 951–6.
113. Anthonisen NR, Manfreda J, Warren CP et al. (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106, 196–204.
114. Gibson PG, Wlodarcyzyk JH, Wilson AJ, Srpgis A (1998) Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. J Qual Clin Pract 18, 125–33.
115. Regueiro CR, Hamel MB, Davis RB, Desbiens N, Connors AF Jr, Phillips RS (1998) A comparison of generalist and pulmonologist care for patients hospitalised with severe chronic obstructive pulmonary disease: resource intensity, hospital costs, and survival. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. Am J Med 15, 366–72.
116. Warre PM, Flenley DC, Millar JS, Avery A (1980) Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961–68 and 1970–76. Lancet i, 467–70.
117. Murphy TF, Sethi S, Klingman KL, Brueggemann AB, Doern GV (1999) Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J Infect Dis 180, 404–9.
118. Soler N, Torres A, Ewig S et al. (1998) Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 157, 1498–505.
119. Stockley RA, O’Brien C, Pye A, Hill SL (2000) Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117, 1638–45.
120. Wilson R (1998) The role of infection in COPD. Chest 113, 242S–8S.
121. Walsh EE, Falsey AR, Hennessey PA (1999) Respiratory syncytial and other virus infections in persons with chronic cardio-pulmonary disease. Am J Respir Crit Care Med 160, 791.
122. Consensus conference report (1999) Clinical indications for non-invasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD and nocturnal hypoventilation. Chest 116, 521–34.
123. Bott J, Carroll MP, Conway JH et al. (1993) Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive pulmonary disease. Lancet 341, 1555–7.
124. Brochard L, Mancebo J, Wysocki M et al. (1995) Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Eng J Med 333, 817–22.
125. Kramer N, Meyer TJ, Meharg J, Cece RD, Hill NS (1995) Randomized prospective trial of non-invasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 151, 1799–806.
126. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS (2003) Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease. Cochrane systemic review and meta-analysis. BMJ 326, 185.
127. Meyer TJ, Hill NS (1994) Noninvasive positive pressure ventilation to treat respiratory failure. Ann Intern Med 120, 760–70.
128. Plant PK, Owen JL, Elliott MW (2000) Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 355, 1931–5.
129. Davies L, Wilkinson M, Bonner S, Calverley PM, Angus RM (2000) ‘Hospital at home’ versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease. Prospective randomised controlled trial. BMJ 321, 1265–8.
130. Hermiz O, Comino E, Marks G, Daffurn K, Wilson S, Harris M (2002) Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease. BMJ 325, 938.
131. Hernandez C, Casas A, Escarrabill J et al. (2003) Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 21, 58–67.
132. Carone M., Jones PW (2000) Health Status quality of life: In: Donner CF, Decramer M, eds. Pulmonary Rehabilitation. Eur Resp Man 13, 22–35.
133. Patrick DL, Erickson P (1993) Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York: Oxford University Press.
134. Bergner M, Bobbitt RA, Carter WB, Gilson BS (1981) The Sickness Impact Profile: development and final revision of a health status measure. Med Care 18, 787–805.
135. Mahler DA, Mackowiak JI (1995) Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patient with COPD. Chest 107, 1585–9.
136. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW (1987) A measure of quality of life for clinical trails in chronic lung disease. Thorax 42, 773–8.
137. Jones PW, Quirk FH, Baveystock CM (1991) The St George’s respiratory questionnaire. Respir Med 85(Suppl B), 25–31.
138. Jones PW, Quirk FH, Baveystock CM, Littlejohns P (1992) A self-complete measure of health status for chronic airflow limitation: the St George’s Respiratory Questionnaire. Am Rev Respir Dis 145, 1321–7.
139. Tu SP, McDonnell MB, Spertus JA, Steele BG, Fihn SD (1997) A new self-administered questionnaire to monitor health-related quality of life in patients with COOD. Ambulatory Care Quality Improvement Project (ACQUIP) Investigators. Chest 112, 614–22.
140. Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349, 1498–504.
141. Prescott E, Bjerg AM, Andersen PK et al. (1997) Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Resp J 10, 822–7.
142. Royal College of General Practitioners, Office of Population Censuses and Surveys, and Department of Health (1995) Morbidity Statistics from General Practice Fourth National Study. 1991–1992. London: HMSO.
143. British Thoracic Society Standards of Case Subcommittee on Pulmonary Rehabilitation (2001) Plumonary Rehabilitation. Thorax 56: 827–34.
144. British Thoracic Society (2003) SIGN – British Thoracic Society Guidelines on the management of asthma 2003. Thorax 58(Suppl1), 1–232.
145. Pauwels R, Buist S, Calverley P et al. (2001) Global strategy for the diagnosis, management and prevention of COPD. Am J Resp Crit Care Med 163, 1256–76.
146. NICE (2004) Chronic Obstuctive Pulmonary Disease: National clinical guide line for management of chronic obstructive pulmonary disease in adults in primary and secondary case. Thorax 59(Suppl1), 1–232.
147. The COPD Guidelines Group of the Standards of Case Committee of the BTS (1997) BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 52(Suppl5), S1–S28.
148. The Nebuliser Project Group of The British Thoracic Society Standards of Care Committee (1997) Current best practice for nebuliser treatment. Thorax 52, S1–106.
149. van Schayck CP, Loozen JMC, Wagena E et al. (2002) Detecting patients at high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 324, 1370–3.
150. British Thoracic Society, Scottish Intercollegiate Guidelines Network (SIGN) (2003) British guideline on the management of asthma. Thorax 58(Suppl1), i1–94.
151. Jonsson JS, Gislason T, Gislason D et al. (1998) Acute bronchitis and clinical outcome three years later: prospective cohort study. BMJ 317, 1433.
152. Stoller JK, Ferranti R, Feinstein AR (1986) Further specification and evaluation of a new clinical index for dyspnea. Am Rev Resp Dis 134, 1129–34.
153. Jorenby DE, Leischow SJ, Nides MA et al. (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340, 685–91.
154. Parrott S, Godfrey C, Raw M et al. (1998) Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax 53, S1A–S38A.
155. Raw M, McNeill A, West R (1998) Smoking cessation guidelines for health professionals – a guide to effective smoking cessation interventions for the health care system. Thorax 53, S1–S19.
156. BTS Nebuliser Guidelines (1997) The nebuliser project group of the British Thoracic Society, standards of care committee. Current best practice for nebuliser treatment. Thorax 52, S1–S106.
157. Burge PS, Calverley PMA, Jones PW et al. (2000) Randomized, double-blind placebocontrolled study of fluticasone propionate in patients with moderate to severe chronic obstuctive pulmonary disease: the Isolde trial. BMJ 320, 1297–303.
158. Burge PS, Calverley PMA, Jones PW et al. (2003) Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 58, 654–8.
159. Jones PW, Bosh TK (1997) Quality of life changes in COPD patients treated with salmeterol. Am J Resp Crit Care Med 155, 1283–9.
160. Lofdahl CG, Postma DS, Laitinen LA, Ohlsson SV, Pauwels RA, Pride NB (1998) The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): Recruitment methods and strategies. Resp Med 92, 467–72.
161. Pauwels RA, Lofdani C, Lattinen LA et al. (1999) Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 343, 1948–53.
162. van Grunsven PM, van Schayck CP, Derenne JP et al. (1999) Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease; a meta-analysis. Thorax 54, 7–14.
163. Vestbo J, Prescott E, Lange P (1996) Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Case Med 153, 1530–35.
164. Vestbo J, Sorensen T, Lange P et al. (1999) Long-term effects of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease; a randomized controlled trial. Lancet 353, 1819–23.
165. Decramer M, Gosselink R, Troosters T et al. (1997) Muscle weakness is related to utilization of health care resources in COPD patients. Eur Resp J 10, 417–23.
166. Lacasse Y, Wong E, Guyatt GH et al. (1996) Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease Lancet 348, 1115–19.
167. Ries AL, Carlin BW, Carlin V et al. (1997) Pulmonary rehabilitation: Joint ACCP/AACVPR evidence-based guidelines. J Cardiopulm Rehabil 17, 371–405.
168. Medical Research Council Working Party (1981) Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet i, 681–6.
169. Roberts CM, Franklin J, O’Neill A, et al. (1998) Screening patients in general practice with COPD for long term domiciliary oxygen requirement using pulse oximetry. Resp Med 92, 1265–8.
170. Smith B, Appleton S, Adams R, Southcott A, Ruffin R (2001) Home care by outreach nursing for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 3, CD000994.
171. Poole PJ, Black PN (2001) Oral mucolytic drugs for exacerbations of COPD: a systematic review. BMJ 322, 1271–4.
172. Bourbeau J, Julien M, Maltais F et al. (2003) Reduction of hospital utilization in patients with COPD; a disease specific self-management intervention. Arch Intern Med 163, 585–91.
173. Monninkhof EM, van derValk PD, van der Palin J et al. (2003) Self-management education for chronic obstructive pulmonary disease. Cochrane Database of Syst Rev 1, CD002990.
174. Watson PB, Town GI, Holbrook N et al. (1997) Evaluation of a self-management plan for chronic obstructive pulmonary disease. Eur Resp J 10, 1267–71.